Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100032, China.
Front Med. 2022 Oct;16(5):773-783. doi: 10.1007/s11684-021-0902-1. Epub 2022 Jul 1.
The total number of cancer patients who are eligible for and will benefit from immune checkpoint inhibitors (ICIs) in China has not been quantified. This cross-sectional study was conducted to estimate the number of Chinese cancer patients with eligibility and response to ICIs based on the 2015 Chinese cancer statistics and the immune checkpoint inhibitor clinical practice guideline of the Chinese Society of Clinical Oncology. A total of 11 ICIs were recommended for 17 cancer types. The estimated number of eligible patients annually was 1 290 156 (55.18%), which included 888 738 males (60.05%) and 400 468 females (46.67%). The estimated number of responders annually was 448 972 (19.20%), which included 309 023 males (20.88%) and 139 764 females (16.29%). Gastric cancer (n=291 000, 12.45%), non-small-cell lung cancer (n=289 629, 12.39%), and hepatocellular carcinoma (n=277 100, 11.85%) were the top three cancer types with the highest number of eligible patients. Non-small-cell lung cancer (n=180 022, 7.70%), hepatocellular carcinoma (n=75 648, 3.24%), and small-cell lung cancer (n=64 362, 2.75%) were the top three cancer types with the highest number of responders. In conclusion, ICIs provide considerable benefit in Chinese cancer patients under optimal estimation.
中国有多少癌症患者有资格使用免疫检查点抑制剂（ICI）并从中获益尚未量化。本横断面研究旨在根据 2015 年中国癌症统计数据和中国临床肿瘤学会免疫检查点抑制剂临床实践指南，估算有资格使用 ICI 且对 ICI 有反应的中国癌症患者数量。共推荐了 11 种 ICI 用于 17 种癌症类型。每年预计有 1290156 名符合条件的患者（55.18%），其中包括 888738 名男性（60.05%）和 400468 名女性（46.67%）。每年预计有 448972 名应答者（19.20%），其中包括 309023 名男性（20.88%）和 139764 名女性（16.29%）。胃癌（n=291000，12.45%）、非小细胞肺癌（n=289629，12.39%）和肝细胞癌（n=277100，11.85%）是符合条件患者数量最多的前三种癌症类型。非小细胞肺癌（n=180022，7.70%）、肝细胞癌（n=75648，3.24%）和小细胞肺癌（n=64362，2.75%）是应答者数量最多的前三种癌症类型。总之，在最佳估计下，ICI 为中国癌症患者带来了可观的获益。
